Cardiology Trials

Cardiology Trials

Health EN ↓ 149 episodes

An exploration of pivotal clinical trials in cardiovascular medicine that have significantly influenced the field. This podcast aligns with our publications on the Cardiology Trial's Substack. cardiologytrials.substack.com

Be sure to visit the podcast's website and support the creator: cardiologytrials.substack.com

Author

Cardiology Trials

Category

Health

Latest episode

Oct 21, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Review of the MERIT-HF trial 22.05.2025

Lancet 1999;353:2001-07 Background: Beta-blockers directly reduce cardiac contractility and myocardial oxygen demand. For decades, they were avoided in patients with acute and chronic heart failure over concerns they would facilitate decompensation of the condition. The therapeutic cornerstones of treatment, prior to the modern era of clinical trials, focused on managing symptoms and quality of li...

Review of the RALES trial 20.05.2025

N Engl J Med 1999;341:709-717 Background: The renin–angiotensin–aldosterone system (RAAS) is activated in patients with systolic heart failure. While this activation initially helps increase blood volume and maintains blood pressure, chronic activation promotes cardiac fibrosis and remodeling. In patients with systolic heart failure, inhibition of the RAAS with angiotensin-converting enzyme inhibi...

Review of the DIG trial 16.05.2025

N Engl J Med 1997;336:525-33 Background: Digoxin is a natural drug that comes from the Foxglove plant (Digitalis purpurea). It has been used for the treatment of congestive heart failure for over 200 years. At the time this trial was undertaken, it was given to the overwhelming majority of patients with severe congestive heart failure. The percentage of patients on digoxin was over 90% in all of t...

Review of the U.S. Carvedilol Heart Failure Study 14.05.2025

N Engl J Med 1996;334:1349-1355 Background Before 1990, the prevailing idea held that the negative inotropy of beta-blockers would harm patients with impaired systolic function. Yet part of the progression of systolic heart failure involved over stimulation of the sympathetic nervous system. Norepinephrine can exert adverse effects on the circulation, both directly and indirectly. Smaller trials o...

Summary and discussion of V-HEFT II and SOLVD 09.05.2025

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Review of the SOLVD trials 08.05.2025

N Engl J Med 1991;325:293-302 N Engl J Med 1992;327:685-691 Cardiology Trial’s Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Background: Systolic heart failure affects millions worldwide and is associated with high mortality and morbidity. If left untreated, the one-year mortality ranges from 15-50%, depending on...

Review of the V-HEFT II trial 06.05.2025

N Engl J Med 1991; 325:303-10 Background Enalapril was found to be superior to placebo for patients with severe, class IV heart failure in the CONSENSUS trial and the regimen of Hydralazine-Isosorbide dinitrate was found to be superior to Prazosin as well as placebo for stable patients with mild heart failure in the original V-HEFT I trial. No sufficiently powered trials in this space had been per...

Summary and discussion of V-HEFT I and CONSENSUS 02.05.2025

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Review of the CONSENSUS trial 01.05.2025

N Engl J Med 1987; 314:1429-35 Background Prior to the publication of this study, digoxin and diuretics were the mainstay of chronic heart failure management. No therapy had yet been shown to reduce mortality or improve heart failure outcomes in patients with severe disease. The results of the V-HEFT trial had been published in the prior year, which demonstrated that the vasodilator combination of...

Review of the V-HEFT I Trial 29.04.2025

N Engl J Med 1986; 314:1547-52 Background Into the mid-1980’s, digoxin and diuretics were the mainstay of chronic disease management for congestive heart failure. Vasodilator agents were also commonly used based on limited data of their favorable hemodynamic effects. No sufficiently powered trials in this space had been performed to assess whether administration of vasodilators or any other agents...

Review of the CULPRIT-SHOCK Trial 17.04.2025

N Engl J Med 2017;377:2419-2432 Background: A small fraction of patients with acute myocardial infarction (5-10%) have cardiogenic shock. These patients have a high baseline mortality. Early revascularization had been established as better than initial stabilization with medical therapy. Many patients with cardiogenic shock due to acute myocardial infarction (AMI) have multivessel disease. The que...

Summary and discussion of MOSCA-FRAIL and SENIOR-RITA 15.04.2025

For full review of the trials, please see https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Review of the SENIOR-RITA trial 10.04.2025

N Engl J Med 2024;391:1673-1684 Background: Non-ST elevation myocardial infarction (NSTEMI) is the most common acute coronary syndrome subtype in adults over 75 years old. However, these patients were underrepresented in landmark NSTEMI trials. Older adults with multiple comorbidities face an increased risk of mortality. While NSTEMI contributes to this risk, they also have competing risks such as...

Review of the MOSCA-FRAIL trial 08.04.2025

JAMA Intern Med 2023;183:407-415 Background: As we have previously discussed, trials comparing invasive versus conservative management in patients with non-ST elevation myocardial infarction (NSTEMI) have yielded mixed results. The average age of participants in these studies was in the 60s, and multiple comorbidities were relatively uncommon. However, many NSTEMI patients seen in clinical practic...

Summary and discussion of TACTICS-TIMI 18, RITA 3 and ICTUS 03.04.2025

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Review of the ICTUS trial 01.04.2025

N Engl J Med 2005;353:1095-1104 Background: Prior trials on revascularization in patients with acute coronary syndromes without ST-segment elevation have yielded mixed results. While FRISC II and TACTICS-TIMI 18 demonstrated a significant reduction in myocardial infarction, this benefit was not observed in RITA 3 . None of these trials showed a significant reduction in mortality. Further research...

Review of the RITA 3 trial 27.03.2025

The Lancet 2002;360:743-751 Background: The TACTICS-TIMI 18 trial showed that an early invasive strategy in beneficial in selected patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI). These positive findings contrasted the findings from some earlier studies. Cardiology Trial’s Substack is a reader-supported publication. To receive new posts and support our work, consid...

Review of the TACTICS-TIMI 18 trial 13.03.2025

N Engl J Med 2001;344:1879-1887 Background: Acute coronary syndrome is broadly categorized into unstable angina, non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI). In unstable angina, there is no rise in cardiac biomarkers, although some challenge this clinical entity in the current era of high sensitivity troponins. In NSTEMI, there is elevation of car...

Summary and discussion of PRAMI, COMPLETE and FULL REVASC 11.03.2025

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Review of the FULL REVASC trial 06.03.2025

N Engl J Med 2024;390:1481-1492 Background: In patients with ST-elevation myocardial infarction (STEMI), opening the culprit artery improves outcomes. Nearly half of STEMI patients have disease in other coronary arteries. Whether revascularizing these non-culprit arteries improves outcomes remained uncertain. The PRAMI trial showed improvement in outcomes with complete revascularization but was re...

Review of the COMPLETE trial 05.03.2025

N Engl J Med 2019;381:1411-1421 Background Percutaneous coronary intervention (PCI) had been clearly established as the standard of care for ST elevation myocardial infarction. Yet many patients taken for PCI have multiple lesions in addition to the culprit. The benefit of routinely treating additional significant lesions has been unclear, with previous smaller trials showing reductions in composi...

Review of the PRAMI Trial 27.02.2025

N Engl J Med 2013;369:1115-23 Background: The COURAGE trial was published in 2007. It compared up-front PCI to medical therapy alone in patients with stable CAD. Preventive PCI did not reduce the chance of dying or having a heart attack over a median follow up time of 5 years. The results rocked the cardiology world because for years prior to the publication of COURAGE, the standard of care called...

Summary and discussion of TAPAS and TASTE 25.02.2025

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Summary and discussion of trials of fibrinolysis vs invasive strategy in STEMI 20.02.2025

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Review of the TASTE trial 18.02.2025

N Engl J Med 2013;369:1587-1597 N Engl J Med 2014;371:1111-1120 Cardiology Trial’s Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Background: In the TAPAS trial, thrombus aspiration in patients with ST elevation myocardial infarction (STEMI) improved coronary reperfusion as evident by coronary blush grade and elec...

Listen to the Cardiology Trials podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.